PepGen Stock Drops 26% on FDA Partial Clinical Hold

Key Summary of FDA Action

PepGen Inc. (NASDAQ:PEPG) shares plunged 26% in after-hours trading after the U.S. Food and Drug Administration (FDA) issued a partial clinical hold on its FREEDOM2-DM1 Phase 2 trial. This action halts new patient enrollment in the U.S.

Situation Overview

The FDA's hold relates to inquiries about preclinical pharmacology and toxicology studies for the PGN-EDODM1 drug candidate. Importantly, the agency did not cite concerns regarding existing clinical data from the prior Phase 1 study. PepGen is currently working to provide the FDA with additional analyses to resolve the issue.

Impact on Market and Operations

The direct financial impact was a 26% drop in PEPG's stock value post-announcement. Operationally, the trial is proceeding outside the U.S., with dosing continuing in the UK and Canada. The trial has also received clearance in South Korea, Australia, and New Zealand.

Summary

Despite the U.S. hold, PepGen maintains its original timeline for data reporting, with initial results expected in the first quarter of 2026. The company is focused on resolving the FDA's questions while advancing the study in other approved regions.

FAQ

Q: Why did PepGen's stock fall?
A: The stock fell 26% because the FDA placed a partial clinical hold on its Phase 2 trial, creating uncertainty.

Q: What is the status of the trial outside the U.S.?
A: The trial continues in several countries, including Canada and the UK, where patient dosing is ongoing.

Source: Investing.com